Axxcess Wealth Management LLC Sells 3,713 Shares of Sanofi (NASDAQ:SNY)

Axxcess Wealth Management LLC lowered its stake in shares of Sanofi (NASDAQ:SNY) by 45.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,440 shares of the company’s stock after selling 3,713 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Sanofi were worth $214,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in SNY. Raymond James Financial Inc. bought a new stake in shares of Sanofi in the fourth quarter valued at approximately $135,933,000. DAVENPORT & Co LLC boosted its position in shares of Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after acquiring an additional 664,455 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after acquiring an additional 399,301 shares during the period. Franklin Resources Inc. raised its stake in shares of Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after purchasing an additional 395,744 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of Sanofi by 107.5% in the third quarter. Barclays PLC now owns 639,772 shares of the company’s stock valued at $36,869,000 after purchasing an additional 331,445 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SNY. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. The Goldman Sachs Group began coverage on Sanofi in a research note on Friday. They issued a “neutral” rating and a $65.00 target price for the company. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Sanofi currently has an average rating of “Moderate Buy” and an average price target of $62.50.

Sanofi Stock Performance

Sanofi stock opened at $56.90 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock has a fifty day moving average price of $54.55 and a two-hundred day moving average price of $52.89. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12. The firm has a market capitalization of $144.40 billion, a P/E ratio of 22.85, a P/E/G ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.